A Phase III Study Comparing Irinotecan, Cisplatin and Etoposide (PEI) with Nogitecan for the Treatment of Relapsed Small-Cell Lung Cancer (JCOG0605).
Phase of Trial: Phase III
Latest Information Update: 13 Jun 2016
At a glance
- Drugs Cisplatin (Primary) ; Etoposide (Primary) ; Irinotecan (Primary) ; Topotecan
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 13 Jun 2016 Primary endpoint has been met. (Overall survival), as per results published in the Lancet Oncology.
- 13 Jun 2016 Status changed from active, no longer recruiting to completed, as per results published in the Lancet Oncology.
- 13 Jun 2016 Results published in the Lancet Oncology